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Abstract
Sepsis is a significant public health problem and is one of the
leading causes of death in critically ill patients admitted to the
intensive care unit. The cost, both in terms of lives lost and annual
healthcare expenditures, from sepsis is staggering. Unfortunately,
despite an increasing understanding of the unique molecular
pathobiology of sepsis, mortality has remained more or less stable
over the past decade. Moreover, promising therapies in preclinical
models of sepsis have universally failed to live up to initial
expectations in subsequent clinical trials. Multiple studies have
demonstrated that apoptosis plays a major role in the pathobiology
of sepsis and acute lung injury, making the apoptosis pathway an
attractive target for therapy. Herein, the role of apoptosis in sepsis
is briefly discussed, highlighting studies with one potential
therapeutic agent targeting the apoptosis pathway.
Weber and colleagues recently demonstrated that the broad
caspase inhibitor VX-166 significantly inhibited lymphocyte
apoptosis and improved survival in two complementary
rodent models of sepsis – endotoxin shock, and cecal ligation
and puncture [1]. Sepsis remains a significant worldwide
public health problem and is currently the 10th leading cause
of death overall in the United States – there are now more
deaths attributable to sepsis than to coronary artery disease,
stroke, or cancer [2]. There are approximately 750,000 cases
of severe sepsis per year in the United States alone, and the
incidence of sepsis is expected to further increase by 1.5%
every year, resulting in an additional 1 million cases per year
by 2020 [2-4]. The financial toll attributed to sepsis is
staggering – the most recent statistics suggest that sepsis
accounts for nearly $17 billion and €5.8–7.6 billion in annual
healthcare expenditures in the United States and in Europe,
respectively [2,4,5]. Sepsis also remains a significant health
problem in children, accounting for nearly 4,500 pediatric
deaths in the United States every year and close to $2 billion
per year in annual healthcare expenditures [6]. These
statistics do not take into account the additional hidden costs
attributed to the loss of productivity related to years of life lost
for both critically ill children and adults who succumb to
sepsis. Based on these sobering statistics, there is great
interest in identifying novel treatments for managing critically
ill children and adults with sepsis.
Unfortunately, promising therapies in preclinical models of
sepsis have universally failed to live up to initial expectations
in subsequent clinical trials [7]. As a matter of record, to date
there have been only two positive clinical trials in critically ill
adults with sepsis – early goal-directed therapy [8], and
activated protein C (drotrecogin alfa, Xigris®; Eli Lilly and Co.,
Indianapolis, IN, USA) [9]. Two additional therapies – adrenal
corticosteroids [10,11] and intravenous immunoglobulins
[12] – have shown promise, although the results on mortality
reduction have been inconsistent. As a result, the search for
novel therapeutic targets for the management of critically ill
patients with sepsis continues – one potential novel
pharmacologic approach to therapy involves targeting the
apoptosis pathway. Of interest, at least one proposed
mechanism for activated protein C involves inhibition of the
apoptosis pathway [13].
The Greek word apoptosis literally refers to the dropping off
of petals or leaves from plants or trees. Apoptosis was first
used to describe an energy-dependent form of programmed
cell death or cell suicide in 1972 by Kerr and colleagues [14].
The importance of apoptosis in the regulation of growth and
development as well as the maintenance of cellular
homeostasis is now widely appreciated [15]. Apoptosis is
characterized morphologically by cell membrane blebbing,
cell shrinkage, chromatin condensation, and DNA fragmen-
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tation. As cells undergo apoptosis, they are phagocytosed by
surrounding macrophages before membrane rupture, thereby
preventing the inflammatory response that occurs via the
release of cell contents by cells undergoing necrotic death.
Apoptosis is classically triggered via two signaling pathways,
the intrinsic pathway (also known as the mitochondrial
pathway) and the extrinsic pathway (also known as the death
receptor pathway). The extrinsic pathway is triggered when
death ligands (for example, FasL, TNFα, AproL, and TRAIL)
bind to their respective cell surface death receptors (Fas,
TNFR1, DR3, DR4, and DR5). Ligand binding results in the
recruitment of several adapter proteins and the subsequent
association and activation of the initiator caspases (cysteine
aspartyl-specific proteases). The caspases are a family of cell
proteases that exist as zymogens within cells and can be
activated by either autocatalytic activation or other proteases.
The initiator caspases (primarily caspase 8 and caspase 10)
subsequently activate the effector caspases (primarily
caspase 3, caspase 6, and caspase 7). Alternatively, the
intrinsic pathway is triggered by intracellular stress, which
leads to mitochondrial outer membrane permeabilization and
release of mitochondrial proteins, such as cytochrome c.
Cytochrome c forms a complex with apoptosis activating
factor 1 and the initiator caspase 9, called the apoptosome.
Caspase 3 is recruited and then activated by the apopto-
some, at which point these two pathways converge. In
addition, there is additional cross-talk between the two
pathways.
The entire process of apoptosis is highly regulated by both
pro-apoptopic and anti-apoptotic factors [15-17]. The
effector caspases execute the apoptosis program by cleaving
other cellular proteins crucial for cell survival [15].
Multiple studies have now demonstrated that apoptosis plays
a major role in the pathobiology of sepsis. For example, there
is extensive evidence for apoptosis of lymphocytes and gastro-
intestinal epithelial cells during sepsis [16,18]. In addition,
apoptosis of both alveolar epithelial cells and respiratory
endothelial cells has been conclusively demonstrated in
animals and humans with acute lung injury and the acute
respiratory distress syndrome [17]. More importantly, the
evidence from several animal models strongly suggests that
inhibition of apoptosis in both sepsis and acute lung injury/
acute respiratory distress syndrome improves survival [17,18].
In the current study, Weber and colleagues demonstrated
that the small-molecule, broad caspase inhibitor VX-166
inhibited both lymphocyte and endothelial cell apoptosis in
vivo and inhibited lipopolysaccharide-mediated IL-1β and
IL-18 release from peripheral blood monocytes [1]. The
effects of VX-166 were then tested in two complementary
rodent models of sepsis – namely, endotoxin shock and cecal
ligation and puncture. VX-166 was administered by either
repeat intravenous bolus or by an implanted mini-osmotic
pump. VX-166 significantly improved survival in both models,
even when administered up to 8 hours following the onset of
sepsis [1]. Additional mechanistic data were provided, show-
ing that VX-166 prevented lymphocyte apoptosis in vivo and
decreased circulating levels of endotoxin and proinflammatory
cytokines in both models.
While these studies are preliminary in nature, the fact that
VX-166 improved survival even when administered well after
the onset of sepsis (a much more clinically relevant model) is
certainly intriguing and provides supportive evidence that
targeting the apoptosis pathway may represent a novel
approach to the management of sepsis in the clinical setting.
Future studies are likely to further elucidate the role of
caspase inhibitors such as VX-166 in critically ill patients with
sepsis.
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